A pharmaceutical two-phase admixture for topical application, transdermal or transmucosal, characterized by components in two phases, a liquid and a solid, adapted for topical application, transdermal or transmucosal, to various skin and/or mucosal surface areas of the body is disclosed. The solid phase is comprised of one or more bio-identical hormones and the liquid phase is comprised of one or more excipient carrier oils. The bio-identical hormone component is comprised of one or more of Bi-Est, testosterone, progesterone, and dehydroepiandrosterone. The excipient carrier oil component is comprised of one or more of a wide range of common and rare pharmacological oils including specific formulations of jojoba oil, evening primrose oil, and borage seed oil. The solid phase bio-identical hormone component is comprised of either a standard coarse formulation or a formulation comprised of nanoparticles. The pharmaceutical admixture is especially useful in a regime of hormone replacement therapy.

A pharmaceutical two-phase admixture for topical application, transdermal or transmucosal, characterized by components in two phases, a liquid and a solid, adapted for topical application, transdermal or transmucosal, to various skin and/or mucosal surface areas of the body is disclosed. The solid phase is comprised of one or more bio-identical hormones and the liquid phase is comprised of one or more excipient carrier oils. The bio-identical hormone component is comprised of one or more of Bi-Est, testosterone, progesterone, and dehydroepiandrosterone. The excipient carrier oil component is comprised of one or more of a wide range of common and rare pharmacological oils including specific formulations of jojoba oil, evening primrose oil, and borage seed oil. The solid phase bio-identical hormone component is comprised of either a standard coarse formulation or a formulation comprised of nanoparticles. The pharmaceutical admixture is especially useful in a regime of hormone replacement therapy.

A pharmaceutical two-phase admixture for topical application, transdermal or transmucosal, characterized by components in two phases, a liquid and a solid, adapted for topical application, transdermal or transmucosal, to various skin and/or mucosal surface areas of the body is disclosed. The solid phase is comprised of one or more bio-identical hormones and the liquid phase is comprised of one or more excipient carrier oils. The bio-identical hormone component is comprised of one or more of Bi-Est, testosterone, progesterone, and dehydroepiandrosterone. The excipient carrier oil component is comprised of one or more of a wide range of common and rare pharmacological oils including specific formulations of jojoba oil, evening primrose oil, and borage seed oil. The solid phase bio-identical hormone component is comprised of either a standard coarse formulation or a formulation comprised of nanoparticles. The pharmaceutical admixture is especially useful in a regime of hormone replacement therapy.

The present application includes a method for introducing a hormone directly into an affected area within a tumor. The method includes penetrating the affected area of the tumor with a biopsy needle in order to obtain a biopsy specimen. The specimen is withdrawn along with the biopsy needle. A hormone implant is inserted into the void space left behind as the specimen was removed. The method may also include directly inserting the implant and a treating substance into the tumor without the removal of the biopsy specimen. The implant may have various shapes in order to maximize surface contact. The implant is also configured to have a time release function to regulate dosage delivery.

The present application includes a method for introducing a hormone directly into an affected area within a tumor. The method includes penetrating the affected area of the tumor with a biopsy needle in order to obtain a biopsy specimen. The specimen is withdrawn along with the biopsy needle. A hormone implant is inserted into the void space left behind as the specimen was removed. The method may also include directly inserting the implant and a treating substance into the tumor without the removal of the biopsy specimen. The implant may have various shapes in order to maximize surface contact. The implant is also configured to have a time release function to regulate dosage delivery.

The present application includes a method for introducing a hormone directly into an affected area within a tumor. The method includes penetrating the affected area of the tumor with a biopsy needle in order to obtain a biopsy specimen. The specimen is withdrawn along with the biopsy needle. A hormone implant is inserted into the void space left behind as the specimen was removed. The method may also include directly inserting the implant and a treating substance into the tumor without the removal of the biopsy specimen. The implant may have various shapes in order to maximize surface contact. The implant is also configured to have a time release function to regulate dosage delivery.

Described herein are nasal pharmaceutical compositions comprising a porous excipient and an active agent, wherein the active agent is loaded onto a surface of the porous excipient located inside pores of the porous excipient, and wherein the composition is adapted for nasal administration. Also described herein are methods of making and using nasal pharmaceutical compositions.

Methods of treating a testosterone deficiency or its symptoms with a pharmaceutical formulation of testosterone esters are provided. In some embodiments, the subject has adequately controlled blood pressure.

Methods of treating a testosterone deficiency or its symptoms with a pharmaceutical formulation of testosterone esters are provided. In some embodiments, the subject has adequately controlled blood pressure.

Methods are described for differentiating stem and post-natal cells into sex hormone-producing cells that can be administered to a patient autologously or allogeneically in order to maintain in balance, or rebalance, their hypothalamic-pituitary-gonadal (HPG) axis.